A practical reference on 内脏脂肪: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
1,8-Cineole 2-exo-monooxygenase (EC 1.14.14.56, CYP3A4) is an enzyme with systematic name 1,8-cineole,NADPH:oxygen oxidoreductase (2-exo-hydroxylating). This enzyme catalyses the following chemical reaction
The photosynthetic partners, or photobionts, of X. parietina belong to the green algal genus Trebouxia, including Trebouxia arboricola and T. irregularis. These algae also exist independently in nature, occurring on both lichen-colonized and lichen-free bark. A study found that the photobiont occupies 7% of the thallus volume in X. parietina. Pigmentation density in the upper cortex varies, regulating light exposure to the algae. The Trebouxia photobiont adjusts its photosynthetic activity seasonally, supporting X. parietina in sunlit environments. As sunlight increases in spring, the photobiont reduces chlorophyll levels and produces protective pigments to dissipate excess light as heat. Chlorophyll concentrations are lowest in spring and peak in winter, balancing light absorption and photoprotection throughout the year. X. parietina associates with diverse photobionts. It primarily partners with Trebouxia decolorans when growing on bark and with T. arboricola on rock. Even within local populations, genetically distinct photobionts often coexist in adjacent thalli. One study identified 36 algal genotypes among 38 epiphytic samples from a single site. Despite T. decolorans being assumed to reproduce asexually, multiple algal strains sometimes occur within a single thallus, suggesting photobiont switching or thallus fusion. This diversity may contribute to X. parietina's adaptability across varied environments. Although free-living algae are abundant, X. parietina selectively associates with Trebouxia species.
Sibabrata Mukhopadhyay, Mumu Chakraborty, Arun Bandyopadhyay, Dipak Kar, Tanima Banerjee, Aditya Konar, Debaprasad Jana, Siddhartha Roy, Santu Bandyopadhyay, Balram Ghosh, Mabalirajan Ulaganathan, Rakesh Johri, Subhash Sharma, Gurdarshan Singh, Bholanath Paul, Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety (August 2013). "Method for treatment of bronchial asthma (Patent US8519154B2)". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) Sujoy K Das Gupta, Abhik Saha, Archana Sharma, Siddhartha Roy, Bhabatarak Bhattacharya (January 2012). "Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis (Patent 7569537)". Retrieved 15 October 2016.{{cite web}}: CS1 maint: multiple names: authors list (link) S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U. Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. B. Chakraborty, I. C. Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, Sudeshna Chowdhury (January 2012). "Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (WO Patent 2,012,140,574)". doi:10.13140/RG.2.1.2784.6488. Retrieved 15 October 2016. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) 1st S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U.
At the northern end of Via Roma stands Piazza Castello, regarded as the heart of the city. The half-pedestrianised square hosts some significant buildings such as Palazzo Reale (Former Savoy Royal House), the Palazzo Madama (which previously hosted the Savoy senate and, for few years, the Italian senate after Italian unification), the former Baroque Teatro Regio di Torino (rebuilt in modern style in the 1960s, after being destroyed by fire), the Royal Library of Turin which hosts the Leonardo da Vinci self-portrait, and the baroque Royal Church of San Lorenzo. Moreover, Piazza Castello hosts a Fascist era building, the Torre Littoria, a sort of skyscraper which was supposed to become the headquarters of the Fascist party, although it never served as such. The building's style is quite different from the Baroque style of Piazza Castello. The square regularly hosts the main open space events of the city, live concerts included.
Sources: en.wikipedia.org
Blue tangs experience three different social modes: territorial, schooling, and wandering. Blue tangs in non-territorial modes form schools and wander, while territorial blue tangs do not. Territoriality reduces competition for food resources because one individual claims both a territory and its resources. Additionally, schooling allows fish to better overcome food defense by others, and wandering allows for individual movement to feeding areas, cleaning stations, and other resources. Social behaviors are affected by outside conditions such as damselfish density, conspecific population density, and life history stage. Those in the territorial mode are aggressive and actively chase intruding blue tangs. They swim slower and feed more frequently than non-territorial blue tangs. Schooling fish form compact groups with other blue tangs in addition to other species. Territorial blue tangs are found most often in the reef flat zone (sandy-bottomed with rocks or coral) and are rarely found in the spur zone (low coral ridges) or groove zone (sandy bottom channels). Territoriality prevalence decreases with increasing damselfish population, and the time of day also does not affect territoriality prevalence. Fish in schooling mode swim fast, eat at intermediate rates, and are not aggressive, even though they are often chased by damselfish. Schooling is most prevalent in areas with high damselfish densities such as the groove zone, spur zone, and crest zone (shallow reef area), while schools are most prevalent near midday. Blue tangs are often seen schooling with midnight parrotfish.
=== Morphology === Polymer morphology generally describes the arrangement and microscale ordering of polymer chains in space. The macroscopic physical properties of a polymer are related to the interactions between the polymer chains.
According to the 2010 census, 40.1% of Belizeans were Catholics, 31.8% Protestants (8.4% Pentecostal; 5.4% Adventist; 4.7% Anglican; 3.7% Mennonite; 3.6% Baptist; 2.9% Methodist; 2.8% Nazarene), 1.7% were Jehovah's Witnesses, 10.3% adhered to other religions (Maya religion, Garifuna religion, Obeah and Myalism, and minorities of the Church of Jesus Christ of Latter-day Saints, Hindus, Buddhists, Muslims, Baháʼís, Rastafarians and other) and 15.5% professed to be irreligious.
=== Origins === Modern dentistry in Chengdu developed in the early 20th century through the work of Western medical missionaries. Ashley Woodward Lindsay, a graduate of the Royal College of Dental Surgeons of Ontario in Toronto, left Canada for Chengdu in 1907. With assistance from physician and missionary Omar L. Kilborn, Lindsay established a dental clinic on Sishengci Street. A history published through China's National Health Commission describes the clinic as marking the beginning of modern dentistry in Chengdu. Sichuan University dates the institutional history of the present hospital to the establishment of the Renji Dental Clinic in 1907. It records the expansion of the clinic into the Renji Dental Hospital in 1912. The hospital describes the 1912 institution as China's first specialized dental hospital. West China Union University, a missionary-founded university established in Chengdu in 1910, subsequently became the principal institutional base for Lindsay's dental work. In 1917, the university established its dental education program. The dental school at West China Union University was the earliest dental education institution in China. Several early faculty members were trained at the University of Toronto Faculty of Dentistry, which credits these dentists with helping introduce a university-based model of dental education to China and with contributing to the development of national dental-education standards. In the late 1920s the medical and dental programs of West China Union University were brought into a combined academic structure.
The mean percentage change in weight at week 72 was −15.0% (95% confidence interval [CI], −15.9 to −14.2) with 5-mg weekly doses of tirzepatide, −19.5% (95% CI, −20.4 to −18.5) with 10-mg doses, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg doses. Weight change in the placebo group was −3.1% (95% CI, −4.3 to −1.9). The FDA approved tirzepatide based on evidence from nine clinical trials of 7,769 participants with type 2 diabetes, of whom 5,415 received tirzepatide. The trials were conducted at 673 sites in 24 countries, including Argentina, Australia, Brazil, Canada, India, Israel, Japan, Mexico, Russian Federation, South Korea, Taiwan, European Union, and the United States (including Puerto Rico). All nine trials were used to assess its safety, and five were used to evaluate its efficacy. The five used in efficacy evaluation included 6,263 adult participants with type 2 diabetes. Four additional trials (NCT03131687, NCT03311724, NCT03861052, and NCT03861039) were included in the safety evaluation, for a total of 7,769 adult participants with type 2 diabetes; therefore, the number of participants representing efficacy findings may differ from the number representing safety findings due to different pools of study participants analyzed for efficacy and safety. Tirzepatide's benefits for the treatment of adult participants with type 2 diabetes were primarily evaluated in five clinical trials. In two of these (NCT03954834 and NCT04039503), participants were randomly assigned to receive either tirzepatide or placebo injection weekly.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.